Expression of osteopontin and osteonectin in breast cancer

Journal of Korean Medical Science

Volumn 13, Issue 6, 1998, Pages 652-657

  Kim, Youn Wha ^a   Park, Yong Koo ^a   Lee, Juhie ^a   Ko, Suk Whan ^a   Yang, Moon Ho ^a  

^a Kyung Hee University Hospital   (South Korea)

Author keywords

Breast neoplasms; Osteonectin; Prognosis; Sialoglycoproteins, osteopontin

Indexed keywords

ESTROGEN RECEPTOR; OSTEONECTIN; OSTEOPONTIN; PROTEIN P53; SIALOGLYCOPROTEIN; SPP1 PROTEIN, HUMAN;

ADULT; ARTICLE; BIOSYNTHESIS; BREAST TUMOR; CHEMISTRY; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PAGET NIPPLE DISEASE;

ADULT; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OSTEONECTIN; OSTEOPONTIN; RECEPTORS, ESTROGEN; SIALOGLYCOPROTEINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032247411     PISSN: 10118934     EISSN: None     Source Type: Journal    
DOI: 10.3346/jkms.1998.13.6.652     Document Type: Article

References (11)

1. Hirota S, Ito A, Nagoshi J, Takeda M, Kurata A, Takatsuka Y, Kohri K, Nomura S, Kitamura Y. Expression of bone matrix protein messenger ribonucleic acids in human breast cancers; possible involvement of osteopontin in development of calcifying foci. Lab Invest 1995; 72: 64-9.
2. Tuck AB, O'Malley FP, Singhal H, Tonkin KS, Harris JF, Bautista D, Chambers AF. Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas. Arch Pathol Lab Med 1997; 121: 578-84.
3. Brown LF, Papadopoulos-Sergiou A, Berse B, Manseau FJ, Tognazzi K, Perruzzi CA, Dvorak HF, Senger DR. Osteopontin expression and distribution in human carcinomas. Am J Pathol 1994; 145: 610-23.
4. Senger DR, Perruzzi CA, Gracey CR. Secreted phosphoproteins associated with neoplastic transformation: close homology with plasma proteins cleaved during blood coagulation. Cancer Res 1988; 48: 5770-4.
5. Bellahcene A, Castronovo V. Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. Am J Pathol 1995; 146: 95-100.
6. O'Malley FP, Harris JF, Doig GS, Kerkvliet N, Saad Z, Bautista D, Tonkin K, Chambers AF. Osteopontin expression is an independent prognostic indicator in lymph node negative breast cancer. The 85th Annual Meeting of United States and Canadian Academy of Pathology 1996: 22A (Abstract only).
7. Jundt G, Schultz A, Berghauser K-H, Fisher L, Gehron-Robey P, Termine JD. Immunohistochemical identification of osteogenic bone tumors by osteonectin antibodies. Virchows Arch [A] 1989; 414: 345-53.
8. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grades in breast cancer, Experience from a large study with long-term follow-up. Histopathotogy 1991; 19: 403-10.
9. Chambers AF, Wilson SM, Kervliet N, O'Malley FP, Harris JF, Casson AG. Osteopontin expression in lung cancer. Lung Cancer 1996; 15: 311-23.
10. Saitoh Y, Kuratsu J, Takeshima H, Yamamoto S, Ushio Y. Expression of osteopontin in human glioma: its correlation with the malignancy. Lab Invest 1995; 72: 55-63.
11. Casson AG, Wilson SM, McCart JA, O'Malley FP, Ozcelik H, Tsao MS, Chambers AF. Ras mutation and expression of the ras-regulated genes osteopontin and cathepsin L in human esophageal cancer. Int J Cancer 1997; 72: 739-45.